## STT: State Street Corporation - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 2.8% below STRENGTH zone (3.0-6.0%); PEG 1.05 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($119.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. State Street Corp Sells 1,675,911 Shares of Citigroup Inc. $C**
- Source: MarketBeat | 20251209T130842 | Neutral | Relevance: 98%
- State Street Corp reduced its stake in Citigroup Inc. by 2.0% in the second quarter, selling 1,675,911 shares, yet still maintaining 82,106,479 shares valued at approximately $6.99 billion. Analysts have a "Moderate Buy" consensus rating for Citigroup, with an average target price of $108.70, and several firms recently raised their price targets. Citigroup reported strong quarterly earnings, beating estimates with $2.24 EPS on $22.09 billion revenue, and also declared a quarterly dividend of $0.60 per share.

**2. State Street Corp Grows Stock Holdings in PepsiCo, Inc. $PEP**
- Source: MarketBeat | 20251209T134700 | Neutral | Relevance: 88%
-  State Street Corp increased its stake in PepsiCo, Inc. by 1.6% in the second quarter, now owning 58,419,849 shares valued at over $7.7 billion. Other institutional investors also adjusted their holdings, and analysts have provided varied ratings and price targets for PepsiCo, with an average "Hold" rating and a target price of $156.90. PepsiCo recently reported quarterly earnings topping estimates and declared a quarterly dividend of $1.4225 per share.

**3. State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251209T131408 | Neutral | Relevance: 87%
-  State Street Corp trimmed its stake in Vertex Pharmaceuticals (VRTX) by 0.1%, holding 11,775,227 shares valued at $5.24 billion. The pharmaceutical company exceeded quarterly expectations with an EPS of $4.80 and revenue of $3.08 billion, despite some insider selling and a slight dip in stock price. Institutional investors own 90.96% of the company, and analysts have a "Moderate Buy" rating with an average target price of $495.53.

**4. State Street Corp Decreases Stock Position in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251209T131200 | Neutral | Relevance: 82%
-  State Street Corp reduced its stake in UnitedHealth Group Incorporated (NYSE:UNH) by 0.9% in the second quarter, selling 411,970 shares and now owning 44,926,544 shares valued at $14.02 billion. Despite this decrease, UnitedHealth Group remains State Street Corp's 29th largest holding, comprising approximately 0.5% of its portfolio. Other institutional investors, such as Brighton Jones LLC and Revolve Wealth Partners LLC, significantly increased their positions in UNH during the same period.

**5. State Street Corp Grows Position in Palantir Technologies Inc. $PLTR**
- Source: MarketBeat | 20251209T130838 | Somewhat-Bullish | Relevance: 82%
- State Street Corp significantly increased its stake in Palantir Technologies Inc. (NASDAQ:PLTR) by 6.9% during the second quarter, now holding over 94 million shares valued at approximately $12.88 billion. This increase comes as Palantir reported strong earnings, beating analyst expectations with revenue up 62.8% year-over-year, and several analysts increased their price targets for the stock. Despite some insider selling, institutional ownership remains high at 45.65%.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 8 ($1.34M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 49.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 13.2% (-0.7%)
- Blackrock Inc.: 8.7% (-1.4%)
- JPMORGAN CHASE & CO: 6.1% (+109.1%)
- State Street Corpora: 4.8% (-2.2%)
- FMR, LLC: 4.0% (+17.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +2.7% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 10.9x attractive for 12% earnings growth. Quality metrics strong (margin 22%). Balance sheet: strong liquidity (8.0x), $7.7B free cash flow. Insider selling cluster ($1.3M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.2B |
| Beta | 1.45 |
| 52W Range | $72.81 - $124.21 |
| Short Interest | 2.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 10.9 |
| Current P/E | 12.2 |
| YoY Growth | 11.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.1% to 2.8% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.2pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Outperforming sector by 3.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.83), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.82% (CS: 80) | Neutral |
| RSI_14 | 68.6 | Neutral |
| MACD Histogram | 0.83 | Bullish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.064x | Above |
| vs SMA200 | 1.190x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $124.07
- **Stop Loss:** $119.23 (3.9% risk)
- **Target:** $128.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 206
- **Position Value:** $25,558.42
- **Portfolio %:** 25.56%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

### Earnings

**Next:** 2026-01-15 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.65 | $2.78 | +5.0% |
| 2025Q2 | $2.36 | $2.53 | +7.1% |
| 2025Q1 | $2.01 | $2.04 | +1.7% |
| 2024Q4 | $2.44 | $2.60 | +6.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*